BaP combination found effective to treat blood cancers

BaP combination found effective to treat blood cancers

Scientists at University of Birmingham have found that the combination of cholesterol-lowering drug, bezafibrate, and a contraceptive steroid, medroxyprogesterone acetate can be effective to treat several blood cancer such as acute myelogenous leukemia (AML), chronic lymphocytic leukaemia (CLL) and non-Hodgkin’s lymphoma.

This study was conducted to determine the mechanism of action of combination of bezafibrate and medroxyprogesterone acetate (BaP) and was published in the ‘Cancer Research’ Journal. The effect of this drug combination was investigated in AML and Burkitt’s lymphoma cells (BL).

The study findings showed that BaP combination blocks the synthesis of stearoyl CoA desaturase, an essential enzyme responsible for production of fatty acids. The fatty acids are required for growth and multiplication of cancer cells, especially blood cancers such as AML, CLL and non hodgkin lymphoma.

The authors concluded that the BaP combination shows real promise for treating blood cancers. Using existing drug combinations outside of their approved indication can be a potential approach to develop effective, affordable and non toxic treatments and an effective clinical strategy to improve patients outcomes such as survival and quality of life.

Also, Learn the differences between several types of blood cancers.

SourceCancer Research
Original title of the articleDrug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids

Leave a Reply

Copyright © 2021 | Powered by: Admac Oncology